Niacin in the prevention of atherosclerosis: Significance of vasodilatation

Medical Hypotheses

Volumn 75, Issue 4, 2010, Pages 397-400

  Tuohimaa, P ^a   Jarvilehto M ^b  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^b UNIVERSITY OF OULU   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINAMIDE; NICOTINIC ACID; PROSTAGLANDIN INHIBITOR; PROSTAGLANDIN RECEPTOR BLOCKING AGENT;

ARTICLE; ATHEROSCLEROSIS; DRUG MECHANISM; FLUSHING; HUMAN; HYPOTHESIS; PRIMARY PREVENTION; PROPHYLAXIS; SIDE EFFECT; VASODILATATION;

ATHEROSCLEROSIS; CELL HYPOXIA; HUMANS; MODELS, BIOLOGICAL; NIACIN; VASA VASORUM; VASODILATION;

EID: 77955577782     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2010.04.007     Document Type: Article

References (37)

1. Brown M.S., Goldstein J.L. A receptor-mediated pathway for cholesterol homeostasis. Science 1986, 232:34-47.
2. Ross R. Atherosclerosis is an inflammatory disease. Am Heart J 1999, 138:S419-420.
3. Friedman G., Ben-Yehuda A., Dabach Y., Hollander G., Babaey S., Ben-Naim M., et al. Macrophage cholesterol metabolism, apolipoprotein E, and scavenger receptor AI/II mRNA in atherosclerosis-susceptible and -resistant mice. Arterioscler, Thromb, Vasc Biol 2000, 20:2459-2464.
4. Järvilehto M., Tuohimaa P. Vasa vasorum hypoxia: initiation of atherosclerosis medical hypotheses 2009.
5. Langheinrich A.C., Kampschulte M., Buch T., Bohle R.M. Vasa vasorum and atherosclerosis - quid novi?. Thromb Haemostasis 2007, 97:873-879.
6. Davidson M.H. Overview of prevention and treatment of atherosclerosis with lipid-altering therapy for pharmacy directors. Am J Manag Care 2007, 13 Suppl 10:S260-269.
7. Kapur N.K., Musunuru K. Clinical efficacy and safety of statins in managing cardiovascular risk. Vasc Health Risk Manag 2008, 4:341-353.
8. Kolovou G.D., Katerina A., Ioannis V., Cokkinos D.V. Simvastatin: two decades in a circle. Cardiovasc Ther 2008, 26:166-178.
9. Canner P.L., Berge K.G., Wenger N.K., Stamler J., Friedman L., Prineas R.J., et al. Fifteen year mortality in coronary drug project patients: long-term benefit with niacin. J Am Coll Cardiol 1986, 8:1245-1255.
10. Brown B.G., Zhao X.Q. Nicotinic acid, alone and in combinations, for reduction of cardiovascular risk. Am J Cardiol 2008, 101:58B-62B.
11. Gille A., Bodor E.T., Ahmed K., Offermanns S. Nicotinic acid: pharmacological effects and mechanisms of action. Annu Rev Pharmacol Toxicol 2008, 48:79-106.
12. Kamanna V.S., Vo A., Kashyap M.L. Nicotinic acid: recent developments. Curr Opin Cardiol 2008, 23:393-398.
13. Chapman M.J., Assmann G., Fruchart J.C., Shepherd J., Sirtori C. Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid - a position paper developed by the European consensus panel on HDL-C. Curr Med Res Opin 2004, 20:1253-1268.
14. Graham I., Atar D., Borch-Johnsen K., Boysen G., Burell G., Cifkova R., et al. European guidelines on cardiovascular disease prevention in clinical practice: full text. fourth joint task force of the European society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2007, 14 Suppl 2:S1-113.
15. Kuusisto J., Andrulionyte L., Laakso M. Atherosclerosis and cardiovascular risk reduction with PPAR agonists. Curr Atheroscler Rep 2007, 9:274-280.
16. Teramoto T., Sasaki J., Ueshima H., Egusa G., Kinoshita M., Shimamoto K., et al. Risk factors of atherosclerotic diseases. Executive summary of Japan atherosclerosis society (JAS) guideline for diagnosis and prevention of atherosclerosis cardiovascular diseases for Japanese. J Atheroscler Thromb 2007, 14:267-277.
17. Vartiainen E., Puska P., Pekkanen J., Tuomilehto J., Jousilahti P. Changes in risk factors explain changes in mortality from ischaemic heart disease in Finland. BMJ 1994, 309:23-27.
18. Wilson P.W., D'Agostino R.B., Levy D., Belanger A.M., Silbershatz H., Kannel W.B. Prediction of coronary heart disease using risk factor categories. Circulation 1998, 97:1837-1847.
19. Quensel M., Agardh C.D., Nilsson-Ehle P. Nicotine does not affect plasma lipoprotein concentrations in healthy men. Scand J Clin Lab Invest 1989, 49:149-153.
20. Rahman M.M., Laher I. Structural and functional alteration of blood vessels caused by cigarette smoking: an overview of molecular mechanisms. Curr Vasc Pharmacol 2007, 5:276-292.
21. Reaven G.M. Syndrome X: 6 years later. J Intern Med Suppl 1994, 736:13-22.
22. Rozanski A., Blumenthal J.A., Kaplan J. Impact of psychological factors on the pathogenesis of cardiovascular disease and implications for therapy. Circulation 1999, 99:2192-2217.
23. Touyz R.M., Schiffrin E.L. Role of endothelin in human hypertension. Can J Physiol Pharmacol 2003, 81:533-541.
24. Drager L.F., Bortolotto L.A., Krieger E.M., Lorenzi-Filho G. Additive effects of obstructive sleep apnea and hypertension on early markers of carotid atherosclerosis. Hypertension 2008.
25. Emre A., Sahin S., Erzik C., Nurkalem Z., Oz D., Cirakoglu B., et al. Effect of hormone replacement therapy on plasma lipoproteins and apolipoproteins, endothelial function and myocardial perfusion in postmenopausal women with estrogen receptor-alpha IVS1-397 C/C genotype and established coronary artery disease. Cardiology 2006, 106:44-50.
26. Cruz M.N., Agewall S., Schenck-Gustafsson K., Kublickiene K. Acute dilatation to phytoestrogens and estrogen receptor subtypes expression in small arteries from women with coronary heart disease. Atherosclerosis 2008, 196:49-58.
27. Zittermann A., Koerfer R. Vitamin D in the prevention and treatment of coronary heart disease. Curr Opin Clin Nutr Metab Care 2008, 11:752-757.
28. Roberts C.K., Chen A.K., Barnard R.J. Effect of a short-term diet and exercise intervention in youth on atherosclerotic risk factors. Atherosclerosis 2007, 191:98-106.
29. Veillard N.R., Mach F. Statins: the new aspirin?. Cell Mol Life Sci 2002, 59:1771-1786.
30. Tolstrup J., Gronbaek M. Alcohol and atherosclerosis: recent insights. Curr Atheroscler Rep 2007, 9:116-124.
31. Deng X.S., Deitrich R.A. Ethanol metabolism and effects: nitric oxide and its interaction. Curr Clin Pharmacol 2007, 2:145-153.
32. Dilaveris P., Giannopoulos G., Riga M., Synetos A., Stefanadis C. Beneficial effects of statins on endothelial dysfunction and vascular stiffness. Curr Vasc Pharmacol 2007, 5:227-237.
33. Koh K.K., Quon M.J., Han S.H., Lee Y., Ahn J.Y., Kim S.J., et al. Simvastatin improves flow-mediated dilation but reduces adiponectin levels and insulin sensitivity in hypercholesterolemic patients. Diabetes Care 2008, 31:776-782.
34. Nagaoka T., Hein T.W., Yoshida A., Kuo L. Simvastatin elicits dilation of isolated porcine retinal arterioles: role of nitric oxide and mevalonate-rho kinase pathways. Invest Ophthalmol Vis Sci 2007, 48:825-832.
35. van der Harst P., Groenewegen H.C., Roks A.J., Buikema H., Zijlstra F., van Gilst W.H., et al. Rosuvastatin attenuates angiotensin II-induced neointimal formation after stent implantation in the rat. Coron Artery Dis 2008, 19:47-53.
36. Yildiz A., Cakar M.A., Baskurt M., Okcun B., Guzelsoy D., Coskun U. The effects of atorvastatin therapy on endothelial function in patients with coronary artery disease. Cardiovasc Ultrasound 2007, 5:51.
37. Pike N.B. Flushing out the role of GPR109A (HM74A) in the clinical efficacy of nicotinic acid. J Clin Invest 2005, 115:3400-3403.